Synthesis of novel sulphonamide derivatives from tunable quinolines with computational studies.
| Title: | Synthesis of novel sulphonamide derivatives from tunable quinolines with computational studies. |
|---|---|
| Authors: | Chavan ND; Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, 632014, India.; Sarveswari S; Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, 632014, India.; Vijayakumar V; Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore, 632014, India. vvijayakumar@vit.ac.in. |
| Source: | Scientific reports [Sci Rep] 2025 Mar 31; Vol. 15 (1), pp. 10972. Date of Electronic Publication: 2025 Mar 31. |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE; PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: London : Nature Publishing Group, copyright 2011- |
| Abstract: | The synthesis of new quinoline-sulphonamide derivatives was accomplished through a meticulous five-step molecular assembly utilizing Suzuki, acid-amine cross-coupling reactions and N-alkylation. The integrity of each derivative was thoroughly confirmed via comprehensive spectroscopic analyses, including 1H and 13C NMR, DEPT-135, 1H-1H COSY, HSQC NMR and HRMS techniques. Subsequently, the absorbance and emission spectra of the newly synthesized derivatives were thoroughly investigated. Absorbance spectra were determined to be restricted within the range of 337 nm to 341.73 nm, with compound 10j exhibiting the maximum wavelength of 341.73 nm; conversely, emission spectra were uniformly detected within the range of 411.70 nm to 429.90 nm upon excitation at 340 nm, with compound 10f demonstrating the highest wavelength of 429.90 nm. Notably, these fluorophores displayed impressive characteristics, with high intensity and significant molar extinction coefficients; quantum yield ranging from 0.015 to 0.558 along with the highest stokes shifts in 10h compound (0.6237 × 10-4) in acetonitrile solvent. Additionally, compound 10p showed strong binding affinity and favorable pharmacokinetic properties through molecular docking studies and ADMET calculations. The electronic structure of the molecules was elucidated using techniques such as density functional theory (DFT) and molecular electrostatic potential (MEP) mapping. Additionally, the calculated global reactivity parameters provided valuable insights. Compound 10p exhibited a distinctly low energy gap compared to other compounds, demonstrating its exceptional properties. The comparison between experimental and theoretical UV-vis spectra with major contribution transition in percentage also showcased the remarkable consistency and quality of the synthesized derivatives, highlighting the significant potential of this work in the field of fluorophore and biological application.; (© 2025. The Author(s).) |
| Competing Interests: | Declarations. Competing interests: The authors declare no competing interests. |
| References: | J Enzyme Inhib Med Chem. 2021 Dec;36(1):1751-1759. (PMID: 34325595); Eur J Med Chem. 2015 Jun 5;97:55-74. (PMID: 25942353); Biomolecules. 2022 Aug 08;12(8):. (PMID: 36008987); Future Med Chem. 2019 Dec;11(24):3161-3178. (PMID: 31838895); J Org Chem. 2007 Jan 19;72(2):683-5. (PMID: 17221999); J Comput Aided Mol Des. 2010 Sep;24(9):771-87. (PMID: 20623318); Bioorg Med Chem. 2013 Jun 1;21(11):3080-9. (PMID: 23602620); Nucleic Acids Res. 2021 Jul 2;49(W1):W5-W14. (PMID: 33893803); Biosensors (Basel). 2015 Jun 18;5(2):337-63. (PMID: 26095660); Carcinogenesis. 1991 Dec;12(12):2227-32. (PMID: 1747921); BMC Complement Med Ther. 2020 Feb 3;20(1):29. (PMID: 32020873); Pharmaceuticals (Basel). 2021 Apr 06;14(4):. (PMID: 33917439); Expert Opin Ther Pat. 2023 Nov;33(11):701-720. (PMID: 37545058); Future Med Chem. 2013 Jul;5(11):1331-40. (PMID: 23859210); Materials (Basel). 2022 Jan 15;15(2):. (PMID: 35057366); Heliyon. 2022 Oct;8(10):e10831. (PMID: 36211997); J Mol Model. 2015 Jun;21(6):150. (PMID: 25994457); ACS Omega. 2024 Jun 14;9(26):28046-28060. (PMID: 38973840); RSC Adv. 2024 Sep 24;14(41):30385-30395. (PMID: 39318459); J Chem Phys. 2010 Nov 7;133(17):174101. (PMID: 21054000); Eur J Med Chem. 2023 Jan 15;246:115011. (PMID: 36516582); RSC Adv. 2024 Jul 8;14(30):21328-21341. (PMID: 38979460); Eur J Med Chem. 2013 Nov;69:373-83. (PMID: 24077528); ACS Omega. 2021 Mar 31;6(14):9731-9740. (PMID: 33869953); Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):3605-10. (PMID: 12655069); Nat Commun. 2023 Jul 7;14(1):4031. (PMID: 37419898); Front Microbiol. 2017 Aug 15;8:1566. (PMID: 28861072); Bioorg Med Chem Lett. 2011 Nov 1;21(21):6322-7. (PMID: 21958545); Cold Spring Harb Perspect Med. 2016 Sep 01;6(9):. (PMID: 27449972); J Biomol Struct Dyn. 2021 Sep;39(14):5083-5092. (PMID: 32588759); Chem Soc Rev. 2013 Feb 7;42(3):845-56. (PMID: 23117144); ACS Chem Neurosci. 2016 Jul 20;7(7):972-83. (PMID: 27100049); RSC Adv. 2024 Apr 23;14(19):13218-13226. (PMID: 38655475); Spectrochim Acta A Mol Biomol Spectrosc. 2020 May 5;232:118166. (PMID: 32106033); Comput Struct Biotechnol J. 2022 Aug 10;20:4271-4287. (PMID: 36051887); Int J Biol Macromol. 2024 Apr;265(Pt 1):130767. (PMID: 38471601); J Am Chem Soc. 2018 Jun 20;140(24):7716-7722. (PMID: 29792690); Heliyon. 2023 Oct 29;9(11):e21315. (PMID: 37954314); J Mater Sci Mater Electron. 2021;32(14):18451-18465. (PMID: 38624760); Heliyon. 2025 Jan 22;11(3):e42105. (PMID: 39931475); RSC Adv. 2024 Jul 4;14(29):21089-21101. (PMID: 38966815); Acta Crystallogr E Crystallogr Commun. 2020 Apr 09;76(Pt 5):651-655. (PMID: 32431926); Molecules. 2019 Oct 07;24(19):. (PMID: 31591293); RSC Adv. 2024 Mar 15;14(13):8905-8920. (PMID: 38495980) |
| Contributed Indexing: | Keywords: ADMET; DFT; Fluorescence; MEP; Molecular docking; Quinoline; Sulphonamide–quinoline; Synthesis; TD-DFT; UV–vis |
| Entry Date(s): | Date Created: 20250331 Latest Revision: 20250403 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC11958747 |
| DOI: | 10.1038/s41598-025-94817-1 |
| PMID: | 40164813 |
| Database: | MEDLINE |
Journal Article